USPTO Patent for Hair Follicle Regeneration

The USPTO has granted Washington University a patent (US12582649B2) for compositions and methods for hair follicle regeneration using TRPV4 activating agents. The patent aims to treat hair loss conditions such as alopecia and telogen effluvium.

USPTO Patent Grant: Dopamine D3 Agonists for CNS Disorders

The USPTO has granted patent US12582648B2 to Bioprojet Pharma for a method of treating central nervous system disorders, including restless leg syndrome and neurodegenerative diseases, using dopamine D3 partial agonists. The patent details specific applications and classifications related to these therapeutic uses.

USPTO Patent US12582642B2 for Treating Bovine Papillomatosis

The USPTO has granted patent US12582642B2 to KINOPHARMA, INC. for a composition and method to treat bovine papillomatosis. The patent covers compounds represented by Formula (I) or their pharmaceutically acceptable salts.

USPTO Grants Patent for Sulfur Compound in Tumor Treatment

The USPTO has granted patent US12582641B2 to SHANGHAITECH UNIVERSITY for a sulfur-containing compound based on a glutarimide skeleton and its application in treating tumors. The patent filing date was February 25, 2020, and the grant date is March 24, 2026.

Donepezil Topical Formulation Patent for Intradermal Use

The USPTO has granted a patent (US12582637B2) to Arctic Therapeutics HF for a topical formulation of donepezil intended for intradermal application. The patent covers compositions and methods of use for this specific formulation.

USPTO Patent Granted for Cancer Treatment with ERK Inhibitors

The USPTO has granted a patent (US12582635B2) to Biomed Valley Discoveries, Inc. for methods of treating cancer with atypical BRAF mutations using ERK inhibitors. The patent covers compositions, methods for treatment, and identification of suitable patient populations.

USPTO Patent Grant for CAH Treatment Compound

The USPTO has granted patent US12582634B2 to Neurocrine Biosciences, Inc. for a compound and synthetic methods for treating congenital adrenal hyperplasia (CAH). The patent covers specific chemical structures and their preparation, aiming to provide new therapeutic options for this condition.

USPTO Patent Grant for Improving Kidney Function

The USPTO has granted patent US12582631B2 to Chinook Therapeutics, Inc. for methods of improving kidney function. The patent, which includes 36 claims, was filed on August 16, 2022, and granted on March 24, 2026.

USPTO Patent Grant: Dapansutrile for Breast Cancer Treatment

The USPTO has granted patent US12582628B2 to Olatec Therapeutics, Inc. for a method of treating breast cancer using dapansutrile, optionally in combination with a checkpoint inhibitor. The patent covers methods of treatment and has an effective date of March 24, 2026.

Nestle Patent for MCTs Improving Cognitive Function

The USPTO has granted Nestle a patent (US12582627B2) for MCT formulations designed to improve cognitive functions, such as memory and executive function, and to prevent or treat mild cognitive impairment (MCI). The patent specifies daily dosages and composition ratios of medium chain triglycerides, particularly octanoic acid.